transplant rejection
The move opens the first non-oncology application for Oncocyte, which acquired the relevant cell-free DNA technology in its merger with Chronix this April.
Natera Q1 Revenues Grow 62 Percent
The company reported $152.3 million in total revenues for the quarter and said the number of tests it processed rose 48 percent from the prior-year quarter.
CareDx Q1 Revenues up 76 Percent
The company reported $67.4 million in total revenues for the quarter and said testing service revenues rose 89 percent year over year.
NY State Department of Health Approves Eurofins Viracor Transplant Rejection Tests
The Viracor TRAC donor-derived cell-free DNA test and TruGraf blood gene expression test both assess rejection status in kidney transplant recipients.
Following the launch of its urine-based Qsant assay later this year, the firm plans to develop updated versions of it with new biomarkers for different disease indications.